Study to Determine Possible Effects of Apalutamide on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer

National Cancer Institute (NCI)
Not yet recruiting ID
For more information, see NCT05521698
This randomized trial investigates the possible effect of apalutamide in patients with non-muscle invasive bladder cancer. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Previous studies have suggested that expression of a protein called epidermal growth factor receptor (EGFR) on tumor cells is related to bladder cancer disease progression. This trial may help doctors evaluate if apalutamide has any effect on EGFR expression in patients with non-muscle invasive bladder cancer.
Apalutamide, Biospecimen Collection, Questionnaire Administration, Transurethral Resection of Bladder Tumor
Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
Edward M Messing, Kyle A. Richards, Michael A. Ahdoot, Juan Chipollini, Sandeep Gurram, Debasish Sundi

See list of participating sites